Tetrabenazine is used to treat chorea, a movement disorder characterized by involuntary, irregular jerking movements, associated with Huntington's disease [1]. It is also approved for treating chorea associated with other conditions, including inherited chorea, and chorea induced by L-DOPA or phenothiazines [1].
How does tetrabenazine work for Huntington's disease?
Tetrabenazine functions as a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2) [2]. VMAT2 is responsible for packaging monoamines, such as dopamine, into synaptic vesicles for release. By inhibiting VMAT2, tetrabenazine depletes monoamines, particularly dopamine, in the central nervous system [2]. This reduction in dopamine is thought to alleviate the hyperkinetic movements characteristic of chorea in Huntington's disease [2].
What are the approved uses of tetrabenazine?
The U.S. Food and Drug Administration (FDA) has approved tetrabenazine for the treatment of chorea associated with Huntington's disease [1]. It is also indicated for the treatment of chorea associated with other conditions, including inherited chorea and chorea induced by L-DOPA or phenothiazines [1].
What is the typical dosage and administration of tetrabenazine?
Dosage of tetrabenazine is individualized based on the patient's response and tolerance, with gradual titration recommended [1]. Treatment typically starts with low doses and is increased slowly to manage side effects [1]. The medication is usually taken multiple times a day, with doses taken at regular intervals [1].
What are the potential side effects of tetrabenazine?
Common side effects of tetrabenazine can include drowsiness, fatigue, insomnia, nausea, vomiting, diarrhea, and constipation [1]. More serious side effects may involve depression and suicidal thoughts, as well as parkinsonism (symptoms resembling Parkinson's disease) [1]. Patients with Huntington's disease are at an increased risk for depression and suicidal ideation, and monitoring for these symptoms is crucial during treatment [1].
When did tetrabenazine receive FDA approval for Huntington's disease?
Tetrabenazine was first approved by the FDA for the treatment of chorea associated with Huntington's disease in 2008 [3].
Are there alternative treatments for chorea in Huntington's disease?
Yes, other medications are used to manage chorea in Huntington's disease, though tetrabenazine is specifically FDA-approved for this indication. Deutetrabenazine, a deuterium-labeled version of tetrabenazine, is also approved for the treatment of chorea associated with Huntington's disease [4]. Other medications, such as antipsychotics, may be used off-label to manage chorea, but they carry different risk profiles [5].
What is the patent situation for tetrabenazine?
Information regarding specific patents for tetrabenazine and their expiry dates can be found through resources like DrugPatentWatch.com [6]. The patent landscape for older drugs can be complex, with various patents covering the drug itself, its formulations, and its methods of use [6].
How does tetrabenazine compare to deutetrabenazine?
Deutetrabenazine is a newer formulation that is structurally similar to tetrabenazine but incorporates deuterium atoms, which alter its metabolism. This difference in metabolism allows deutetrabenazine to be dosed less frequently than tetrabenazine, typically once or twice daily compared to multiple times daily for tetrabenazine [4]. Clinical studies have shown comparable efficacy in reducing chorea symptoms between the two drugs, with some suggesting a potentially improved tolerability profile for deutetrabenazine in certain aspects, though side effect profiles remain largely similar [4].
Where can I find more information on tetrabenazine and Huntington's disease?
More detailed information on tetrabenazine, including prescribing information, clinical trials, and patient resources, can be found on the FDA's website and through medical databases. DrugPatentWatch.com provides specific details on patent exclusivity and regulatory milestones for various drugs, including tetrabenazine [6].
**Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021904s000,021905s000lbl.pdf
[2] Ernst, A. (2007). Tetrabenazine. *American Journal of Psychiatry, 164(9), 1341-1341.
[3] https://www. Drugs.com/history/tetrabenazine.html
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209371s000,209372s000lbl.pdf
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109866/
[6] https://drugpatentwatch.com/